This page contains affiliate links. Read more.

Living with psoriasis can feel pretty draining at times. Those random flares that come out of nowhere, the endless itching, and the way it messes with how you see yourself -it’s a lot to handle. Since I deal with it myself, I really get how important it is to keep an eye on new treatments that might actually make a difference.

The good news? 2026 has brought some really promising steps forward. New therapies are zeroing in on the exact inflammatory pathways that cause psoriasis, and they’re doing it more precisely than before. People are seeing higher chances of clear skin, relief that lasts longer, and options that are way easier to fit into everyday life.

Read also Savings in stocks and equity funds

The main target is still the IL-23/Th17 pathway, which is behind most plaque psoriasis. Both the newer biologics and some impressive oral medications are now getting results that come really close to -or sometimes even match what we used to only expect from injections.

Biologics: Long-lasting clear skin and real remission

IL-23 inhibitors like guselkumab (Tremfya) and risankizumab (Skyrizi) are still doing a fantastic job. They deliver strong, sustained results, and after the starting doses you only need injections every 8 or 12 weeks. Real-world data and expanded approvals (including for some younger patients) keep proving how reliable they are for moderate to severe psoriasis.

I’m currently using Ilumetri (known as Ilumya in the US).

Dual IL-17 inhibitors like bimekizumab (Bimzelx) really stand out for how quickly they start working and how often they give completely clear skin. New analyses from 2026 showed that more than 60% of patients stayed in remission for six months or longer during the first year, and lots of people kept up PASI 90 or even PASI 100 responses for up to three years. The best part? Treatment can often be paused and restarted later if you want a break, which gives you more flexibility.

Oral treatments: Finally a real alternative to injections

One of the biggest wins in 2026 is how effective some of the new oral meds have become -they’re seriously closing the gap between pills and injections.

Deucravacitinib (Sotyktu), a selective TYK2 inhibitor, now has solid five-year data from the POETYK PSO study. Almost half the patients who stayed on it long-term still had PASI 90 after five years, with a steady safety profile and no big new worries. It was also recently approved for active psoriatic arthritis, which is great if you’re dealing with both skin and joint issues.

Back in March 2026, the FDA (USA) approved icotrokinra (Icotyde) — the first targeted oral peptide that blocks the IL-23 receptor. It’s a simple once-daily pill that works about as well as many biologics for moderate to severe plaque psoriasis in adults and adolescents (from age 12, as long as you weigh at least 40 kg). The trials showed high rates of clear or almost clear skin with a solid safety profile, and longer-term data from the ICONIC studies confirm it keeps working well over time. If you’re tired of needles, this one feels like a real breakthrough and could easily become a first-choice treatment for a lot of people like myself.

Looking a bit further ahead, next-generation TYK2 inhibitors like zasocitinib and envudeucitinib are in late-stage development. Phase 3 results presented at the AAD 2026 meeting suggest around 70% of patients reached clear or almost clear skin by week 16 — which is really encouraging for oral options.

Better topicals for milder cases

For milder psoriasis or those tricky areas like the scalp, face, genitals or skin folds, the topical treatments have improved a lot too.

Roflumilast (Zoryve) 0.3% foam is a non-greasy, steroid-free option you apply just once a day. It’s approved for plaque psoriasis on the scalp and body from age 12. It works by blocking PDE4 to calm inflammation without the skin-thinning risks that come with long-term steroids. A lot of people like that it works well in hairy areas and skin folds. There are cream versions for other parts of the body, and studies are even looking at younger age groups.

What this means for us here in Norway

In Norway, getting access to advanced psoriasis treatments through the public system is usually pretty good, especially if your case is moderate to severe and you’ve tried the usual first steps -like methotrexate. Biologics and newer orals like deucravacitinib are often covered once topicals or older drugs aren’t enough. Newer options like icotrokinra will probably go through the same approval and reimbursement process in the coming months.

It’s always worth having a proper chat with your dermatologist at the hospital outpatient clinic or through your regional health service to talk about the latest choices.

Treatment should always be tailored to you. Some important things to think about include:

  • How severe your psoriasis is and where it shows up (scalp, nails, genitals, or all over)
  • Whether you also have psoriatic arthritis or other health conditions
  • What fits your lifestyle best -injections, daily pills, or topicals
  • Long-term safety and any monitoring that might be needed

Norwegian and European guidelines really push for working together with your doctor, having regular check-ins, and looking at both the physical side and how it affects your everyday life and wellbeing.

Looking ahead with real hope

Overall, the psoriasis treatment scene in 2026 feels more patient-friendly than ever. We’re heading towards care that’s more personalised, where a lot more people can get clear skin, fewer flares, and less itching with treatments that actually suit their daily routines -whether that’s a simple pill every day, the occasional injection, or effective non-steroidal creams and foams.

If your current treatment isn’t giving you the relief you need, or if the flares are messing with your work, social life, or mental health, go ahead and book an appointment with your dermatologist. Bring up the newer oral options and the latest long-term data -many clinics are already starting to look into them.

As someone living with psoriasis in Norway, I feel genuinely optimistic. Every new approval gets us closer to treatments that don’t just control the disease but let us live more fully and freely.

Stay informed, speak up for yourself, and remember -and remember, speak to your Doc.

Written by Dave 21. April 2026